TY - JOUR
T1 - BRAF as a positive predictive biomarker
T2 - Focus on lung cancer and melanoma patients
AU - Malapelle, Umberto
AU - Rossi, Giulio
AU - Pisapia, Pasquale
AU - Barberis, Massimo
AU - Buttitta, Fiamma
AU - Castiglione, Francesca
AU - Cecere, Fabiana Letizia
AU - Grimaldi, Antonio Maria
AU - Iaccarino, Antonino
AU - Marchetti, Antonio
AU - Massi, Daniela
AU - Medicina, Daniela
AU - Mele, Fabio
AU - Minari, Roberta
AU - Orlando, Elisabetta
AU - Pagni, Fabio
AU - Palmieri, Giuseppe
AU - Righi, Luisella
AU - Russo, Alessandro
AU - Tommasi, Stefania
AU - Vermi, William
AU - Troncone, Giancarlo
PY - 2020/12
Y1 - 2020/12
N2 - In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.
AB - In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.
KW - BRAF
KW - Lung cancer
KW - Melanoma
KW - Precision medicine
KW - Predictive molecular pathology
UR - http://www.scopus.com/inward/record.url?scp=85092188397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092188397&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2020.103118
DO - 10.1016/j.critrevonc.2020.103118
M3 - Review article
AN - SCOPUS:85092188397
VL - 156
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
M1 - 103118
ER -